Rapalogs and mTOR inhibitors as anti-aging therapeutics
Open accessThe DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest experimental support to date as a potential anti-aging therapeutic in mammals. Unlike many other compounds that have been claimed to influence longevity, rapamycin has been repeatedly tested in long-lived, genetically heterogeneous mice, in which it extends both mean and maximum life spans. However, the mechanism that accounts for these effects is far from clear, and a growing list of side effects make it doubtful that rapamycin would ultimately be beneficial in humans. This Review discusses the prospects for developing newer, safer anti-aging therapies based on analogs of rapamycin (termed rapalogs) or other approaches targeting mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rapamycin and its analogs (so-called ‘rapalogs’) suppress the SASP by inhibiting mTOR and appear to extend healthspan and lifespan in mice105,108,109.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In fact, reviewing the effects of other interventions like rapalogs and sirtuins also shows that they may be impacting many of the similar hallmarks of aging (Lamming et al. 2013, Grabowska et al. 2017).”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as Lamming et al. 2013
The cited source says what the claim attributes to it.
In the citing paper
“Many of the side effects of rapamycin, which include immunosuppression, hyperlipidemia and hyperglycemia, have raised concerns about the feasibility of using rapamycin to promote healthy longevity in humans and slowed clinical evaluation of mTOR inhibitors for diseases of aging 26.”
From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [26]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“SASP inhibitors (senomorphics) can directly or indirectly attenuate the SASP of senescent cells by inhibiting transcription factor nuclear factor (NF)-κB, the JAK-STAT signal transduction pathway, the serine/threonine protein kinase mTOR, mitochondrial complex-1-related or 4-related targets, or other pathways involved in the induction and maintenance of the SASP103–106.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“no senolytic compounds developed to date are able to eliminate all types of senescent cells; further they retain a low level of toxicity to young normal cells (Lamming et al., 2013).”
From Single senescent cell sequencing reveals heterogeneity in senescent cells induced by telomere erosion (2019) · cites this paper as Lamming et al., 2013
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227 · cited 2×
“the autophagy-initiating kinase ULK1 (46).”
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 14×
“We might therefore expect other compounds that activate AMPK to specifically inhibit mTORC1 activity.”
BackgroundInfluentialAMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849 · cited 1×
“phorylation of TSC2 and the inhibitory phosphorylation of raptor, an essential component of mTORC1 (92, 93).”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., & Sabatini, D. M. (2010) · Cell · doi:10.1016/j.cell.2010.02.024 · Cited by 2,464 · cited 1×
“The Rag proteins activate mTORC1 by localizing mTORC1 to the lysosome via interaction with the ragulator complex (110).”
BackgroundSelf-citationProlonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365 · cited 1×
“This effect was first observed in certain cultured cell lines (73), and we have recently shown that it also occurs in vivo in multiple tissues including liver, muscle, and adipose (see Figure 2).”
BackgroundSelf-citationLaplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170 · cited 1×
“through a wide variety of signaling mechanisms and have roles in many aspects of physiology, which have been reviewed in depth (9).”
BackgroundSelf-citationFranceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F., Panourgia, M. P., Invidia, L., Celani, L., Scurti, M., et al. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.11.016 · Cited by 2,087 · cited 1×
“Chronic, low-grade inflammation is a feature of aging, and almost every chronic disease has an inflammatory component (71).”
BackgroundA mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · cited 2×
“Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.”
Background
Cited by
Items 401–500 of 565
Gupta, V., Crudu, A., Matsuoka, Y., Ghosh, S., Rozot, R., Marat, X., Jäger, S., Kitano, H., & Breton, L. (2019) · npj Systems Biology and Applications · doi:10.1038/s41540-019-0119-y · Cited by 5
Discovery of Novel 2-aminonicotinonitrile Derivatives With New Potential Autophagy Activity
Zhang, P., Zheng, Z., Yang, X., Zhang, Y., Hu, G., Wang, R., Dong, Y. J., & Wei, D. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0244 · Cited by 5
Hautalterung – zelluläre Seneszenz: Wohin geht die Reise?
Scharffetter‐Kochanek, K., Wang, Y., Makrantonaki, E., Crișan, D., Wlaschek, M., Geiger, H., & Maity, P. (2023) · Die Dermatologie · doi:10.1007/s00105-023-05201-x · Cited by 5
Calorie Restriction Mimetics: Progress and Potential
Roth, G. S., & Ingram, D. K. (2015) · Healthy ageing and longevity · doi:10.1007/978-3-319-14830-4_10 · Cited by 5
Suzuki, J., Yoshioka, K., Kurita, M., 杉本, 拓., Eguchi, T., Ito, N., Kodama, A., Kamei, Y., Ohtani, M., Matsutomo, T., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.04.006 · Cited by 5
Barzilai, D. A. (2025) · Aging · doi:10.18632/aging.206189 · Cited by 5
Aging and anti-aging strategies: A review of past and future therapeutics
Wei, Y., Xiong, B., Song, Z., Zhong, S., Zheng, N., Zhang, A., Chen, Y., & Sun, H. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118340 · Cited by 4
Dietary Restriction in C. elegans
Zhang, Y., & Mair, W. B. (2016) · Healthy ageing and longevity · doi:10.1007/978-3-319-44703-2_16 · Cited by 4
Alfatah, M., Zhang, Y., Naaz, A., Cheng, T. Y. N., & Eisenhaber, F. (2024) · Biology Direct · doi:10.1186/s13062-024-00455-4 · Cited by 4
“The clinically approved drug rapamycin inhibits TORC1 and it extends the murine lifespan and healthspan [44– 46].”
BackgroundChen, D., Xu, W., Wang, Y., Ye, Y., Wang, Y., Yu, M., Gao, J., Wei, J., Dong, Y., Zhang, H., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.076 · Cited by 5
Engin, A. B., & Engin, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49844-3_2 · Cited by 4
Longevity as a Complex Genetic Trait
Sutphin, G. L., & Korstanje, R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-411596-5.00001-0 · Cited by 5
The crosstalk between autophagy and ferroptosis in pulmonary fibrosis
Liu, R., Zheng, D., Wang, F., Jiang, M., Zhao, R., Bao, S., Zhao, X., & Cheng, D. (2025) · Journal of Biomedical Research · doi:10.7555/jbr.39.20250243 · Cited by 4
Evolutionary genetics of ageing
Dönertaş, H. M., & Partridge, L. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-026-00959-x · Cited by 3
“Rapamycin and rapalogues extend lifespan in model organisms by modulating autophagy, proteostasis and inflammatory pathways 83,84 .”
Genetically targeted mTORC1 inhibitor reveals transcriptional control by nuclear mTORC1
Zhong, Y., Sahan, A. Z., Shao, Z., Zhang, Q.-Y., Zhou, X., Haggett, J. G., Koshizuka, K., Myers, S. A., Gutkind, J. S., & Zhang, J. (2026) · Nature Chemical Biology · doi:10.1038/s41589-026-02188-z · Cited by 3
“…mTORC1-interacting motifs 26 ; second, PRAS40 is a relatively small protein and a smaller inhibitory peptide can be derived from it; third, signaling regulation of PRAS40 is well understood, particularly on a few key residues, allowing us to engineer a peptide free from other signaling controls.”
Organoids: generation strategies, applications, and future challenges
Yin, H., Zhu, G., Hai-zhan, W., Yang, B., Wang, Z., & Xie, H. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-05045-x · Cited by 3
“As previously mentioned, organoids can be used to test the efficacy of senescent cell scavengers such as Navitoclax or the combination of dasatinib and quercetin in clearing senescent cells [132] and improving tissue function [149–151].”
Gile, B., Bulbule, S. R., Toriola, M. A., Ruan, B. T., Marium, S., (23810252), A. B., Grach, S. L., Mueller, M., Bateman, L., Bell, J., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08575-3 · Cited by 3
“While it has been widely reported that chronic rapamycin therapy can result in hyperlipidemia, impaired glucose metabolism, and immunosuppression [75], we did not observe clinically significant changes in these safety laboratory parameters, nor did we observe an increase in common or opportunistic…”
Rapamycin’s Role in Periodontal Health and Therapeutics: A Scoping Review
Joshi, V., Gururaj, S. B., Thumbigere‐Math, V., Kugaji, M. S., & Kandaswamy, E. (2025) · JDR Clinical & Translational Research · doi:10.1177/23800844251366967 · Cited by 5
“Rapamycin has garnered significant attention in geroscience for its ability to modulate aging processes and extend the lifespan across diverse models, including flies and mammals (Vellai et al. 2003; Kapahi et al. 2004; Harrison et al. 2009; Johnson, Rabinovitch, et al. 2013; Lamming et al. 2013).”
Dictyostelium discoideum: A Model System to Study Autophagy Mediated Life Extension
Jain, P., Sharma, P., Shrivastava, A., & Saran, S. (2016) · Springer eBooks · doi:10.1007/978-981-10-2155-8_2 · Cited by 4
“One such molecule, rapamycin, an inhibitor of TOR signaling, has already been shown to increase lifespan in a variety of organisms, including most recently, mice (Lamming et al. 2013).”
BackgroundKos, O., Alexander, C., Brandenburg, K., Chen, Z., Heini, A. F., Heumann, D., Khatri, I. A., Mach, J. P., Rietschel, E., Tersikh, A., et al. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.02.010 · Cited by 4
“Rapamycin (Wyeth Chemicals) was injected ip at 48 h intervals as indicated at a dose of 1mg/Kg/mouse [26,27].”
MethodTorshin, I. Y., Николаевна, Р. А., Павловна, Л. Н., & Громова, О. А. (2020) · Obstetrics Gynecology and Reproduction · doi:10.17749/2313-7347/ob.gyn.rep.2020.152 · Cited by 3
Role and Molecular Mechanisms of Lysosomes and Cathepsins in Neuropathology and Aging: New Insights
Khawar, M. B., Naz, F., Hassan, A. M., Sheikh, N., Nabeela, A. H., Rabia, M., Maryam, M., Arif, A., Zaira, A., Zerwa, S., et al. (2021) · Journal of Neurodegenerative Disorders · doi:10.36959/459/605 · Cited by 3
Hayatine inhibits amino acid-induced mTORC1 activation as a novel mTOR-Rag A/C interaction disruptor
Lü, M., Yu, L., Yang, Y., Zhu, J., Qiang, S., Wang, X., Wang, J., Tan, X., Wang, W.-F., Zhang, Y., et al. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.10.014 · Cited by 3
Senolytic Phytocompounds in Redox Signaling
Thirumurugan, K. (2021) · Healthy ageing and longevity · doi:10.1007/978-3-030-84965-8_12 · Cited by 3
Hydroxytyrosol-1-Glucopyranoside Alleviates Senescence via Nrf2 and AMPK Signaling Pathway
Guo, Y., Zhang, B., Han, Y., Muhammad, W. I., Wang, J., Shen, X., Liang, H., Sun, X., & Yuan, Q. (2024) · Records of Natural Products · doi:10.25135/rnp.460.2403.3166 · Cited by 3
“In recent years, medicines such as metformin (MET) [5, 6], rapamycin analogues [7, 8], senolytics [9], sirtuin activators [10], NAD + precursors [11, 12], among others, have shown anti-aging properties, while further research is required to verify their effectiveness.”
Kosach, V., Cherednyk, O. V., & Хоруженко, А. І. (2015) · Biopolymers and Cell · doi:10.7124/bc.0008c7 · Cited by 3
“The re fore, mTOR is considered as a perspective target of anti-cancer and anti-aging therapies [2].”
Backgroundal., A.-A. M. F. A.-H. E., Saud, H. A., & Al–Noor, S. S. (2024) · University of Thi-Qar Journal of agricultural research · doi:10.54174/hfpbwr68 · Cited by 2
Game changer: Navigating between challenges and hopes in geropharmacology
Chen, Q., Hartman, R., Dankiv, L., Yan, E., Young, L. H., & Barsotti, R. (2025) · Advances in pharmacology · doi:10.1016/bs.apha.2025.02.007 · Cited by 2
RLX-201, a Novel mTORC1 Inhibitor With Potential to Promote Skin Longevity and Cellular Health
Randhawa, M., Bojanowski, K., Ferraro, T., Cao, Z. F. H., Day, D., & Mehta, R. (2025) · Dermatologic Surgery · doi:10.1097/dss.0000000000004805 · Cited by 2
Aging reimagined: Bridging clinical modulation and scientific breakthroughs
Mhamdi, S., Chamari, K., BaHammam, A. S., Alkeridy, W. A., Aldeeri, A., & Saad, H. B. (2025) · Biology of Sport · doi:10.5114/biolsport.2026.156224 · Cited by 3
Yang, K., He, Y., Leng, J., Lu, T., Wang, Y., Xie, K., Song, T., Chen, Z., & Zhang, L. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05464-6 · Cited by 2
“…and FCD, targeting this pathway has become a major focus of therapeutic innovation. mTOR inhibitors, particularly rapamycin and its analogs, are currently under investigation for their potential to suppress seizure activity and mitigate abnormal cortical development in FCD patients[31, 32].”
Torrent, C., Gagliardi, C., Fülle, N., Antignano, I., Bernis, M. E., Stork, M., Bano, D., Capasso, M., & Keane, L. (2026) · PLoS ONE · doi:10.1371/journal.pone.0343183 · Cited by 2
“This is particularly pertinent given the increasing clinical interest in rapamycin and rapalogs as geroprotective interventions [50,51].”
VvTOR Responds to ABA Signal and Affects Sugar Related Genes Expression in Grape
Zhao, Y., & Wang, X. Q. (2022) · Russian Journal of Plant Physiology · doi:10.1134/s1021443722020236 · Cited by 2
Hypothesis: functional age and onset of autosomal dominant genetic prion disease
Bordonaro, M. (2023) · Theory in Biosciences · doi:10.1007/s12064-023-00389-x · Cited by 2
“Treatments of gPrD model mice with rapamycin or similar agents (Harrison et al. 2009; Lamming et al. 2013; Blagosklonny 2019; Crutcher et al. 2019; Reita et al. 2019, Herras-Sandoval et al. 2020) that inhibit mTOR and suppress aging in mouse models (Rubenstein et al.”
BackgroundZia, A., Sahebdel, F., Farkhondeh, T., Pourbagher‐Shahri, A. M., Samini, F., & Samarghandian, S. (2025) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010328697250210065420 · Cited by 3
Fight against Glucose Rescues Age-Related Cognitive Decline
(2016) · Neuroscience Communications · doi:10.14800/nc.862 · Cited by 2
“In addition, metformin has been shown to inhibit mammalian target of rapamycin complex 1signaling and increase longevity in mice ([32]).”
BackgroundDoes sugammadex increase the susceptibility of opioid induced chest wall rigidity?
Başaranoğlu, M., Bakan, M., & Umutoğlu, T. (2013) · PubMed · Cited by 2
Inhibition of mTOR Signalling: A Potential Anti-aging Drug Strategy
Saraswat, K., Kumar, R., & Rizvi, S. I. (2018) · Springer eBooks · doi:10.1007/978-981-13-1699-9_10 · Cited by 2
Čepelak, I., & Dodig, S. (2019) · Rad Hrvatske akademije znanosti i umjetnosti Medicinske znanosti · doi:10.21857/moxpjhglzm · Cited by 3
Wang, L., Yan, F., Shi, Y., Su, X., & Zhang, Y. (2023) · Toxicology in Vitro · doi:10.1016/j.tiv.2023.105711 · Cited by 2
Baranov, I. A., Гладин, Д. П., & Козлова, Н. С. (2023) · Russian Biomedical Research · doi:10.56871/rbr.2023.18.67.009 · Cited by 2
Direct modulation of TRPM8 ion channels by rapamycin and analog macrolide immunosuppressants
Tóth, B. I., Bazeli, B., Janssens, A., Lisztes, E., Kelemen, B., Herczeg, M., Nagy, T. M., E. Kövér, K., Mitra, A., Borics, A., et al. (2025) · Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) · doi:10.5281/zenodo.17143201 · Cited by 2
mTORC2 takes the longevity stAGE
Lamming, D. W. (2014) · Oncotarget · doi:10.18632/oncotarget.2457 · Cited by 2
Self-citationDirect modulation of TRPM8 ion channels by rapamycin and analog macrolide immunosuppressantsPreprint
Tóth, B. I., Bazeli, B., Janssens, A., Lisztes, E., Racskó, M., Kelemen, B., Herczeg, M., Nagy, T. M., Kövér, K. E., Mitra, A., et al. (2025) · eLife · doi:10.7554/elife.97341 · Cited by 2
“Our study demonstrates that, in addition to its well-established inhibitory effect on the mTOR signaling pathway ( Abraham and Wiederrecht, 1996 ; Lamming et al., 2013 ), rapamycin acts as an agonist of the ion channel TRPM8.”
Cell-to-Cell Communication in Aging: Mechanisms, Impact and Therapeutic Prospects
Mas‐Bargues, C., Sanz‐Ros, J., Huete-Acevedo, J., & Borrás, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-55022-5_8 · Cited by 2
Murillo-Cancho, A. F., Lozano‐Paniagua, D., Martín‐Latorre, M. D. M., Ramírez-Santos, J., & Soriano, B. J. N. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.103277 · Cited by 1
de Barcelos, S. M., Silva-Carvalho, A. É., Perecin, F., & Carvalho, J. L. (2026) · Molecular Reproduction and Development · doi:10.1002/mrd.70113 · Cited by 1
“In contrast, senomorphics do not eliminate senescent cells but mitigate their deleterious effects by suppressing SASP through the modulation of pathways including NF‐κB, JAK‐STAT, and mTOR (Xu et al. 2015; Tilstra et al. 2012; Lamming et al. 2013).”
Rejuvenation on the Road to Pluripotency
Sarkar, T. J., & Sebastiano, V. (2016) · InTech eBooks · doi:10.5772/63219 · Cited by 1
“iPSCs are very similar to the stable, naturally occurring pluripotent state of ESCs, in terms of both epigenetics and gene expression [52].”
BackgroundVaiserman, A. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12295-4 · Cited by 1
Hyperplasie bénigne de la prostate et incontinence urinaire
Cornu, J. (2020) · The French Journal of Urology · doi:10.1016/s1166-7087(20)30194-9 · Cited by 1
Health and Pro-Longevity Interventions
Vaiserman, A. M., & Lushchak, O. V. (2020) · Healthy ageing and longevity · doi:10.1007/978-3-030-52663-4_27 · Cited by 1
Gerontological Treatment Protocols: An Ethical Inquiry
Fletcher, D.-J. (2021) · Springer eBooks · doi:10.1007/978-981-16-0013-5_5 · Cited by 1
Exercise-Mediated Autophagy and Brain Aging
Kou, X., Zhang, H., Guo, Y. L., Kirberger, M., & Chen, N. (2021) · Springer eBooks · doi:10.1007/978-981-16-4525-9_6 · Cited by 1
Pharmacologic approaches to reduce arterial stiffness
Cecelja, M., & Chowienczyk, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91391-1.00050-9 · Cited by 1
Piskovatska, V., Strilbyska, O., Storey, K. B., Vaiserman, A. M., & Lushchak, O. V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.62134-7 · Cited by 1
Antiaging drugs, candidates, and food supplements: the journey so far
Yodhaanjali, J. R., Surya, R., Sumukha, K. C., Harini, G., Deshpande, G., Chandan, S. A., & Achar, R. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90235-9.00016-1 · Cited by 1
Autophagy in Aging and Longevity
Nakamura, S., Shioda, T., & Yoshimori, T. (2022) · Springer eBooks · doi:10.1007/978-981-16-7977-3_11 · Cited by 1
The role of glycerol–water mixtures in the stability of FKBP12-rapalog-FRB complexes
Lopez, J. J. D., Gaza, J. T., & Nellas, R. B. (2023) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2023.108556 · Cited by 1
Wu, W., Fan, W., Wang, Y.-K., & Huang, W.-H. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0214 · Cited by 1
Candidate molecular targets uncovered in mouse lifespan extension studies
Vedunova, M. V., Borysova, O., Kozlov, G., Zharova, A.-M. D., Morgunov, I., & Moskalev, A. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2346597 · Cited by 1
“Nonetheless, the application of rapamycin to promote robust human longevity has elicited concerns, chiefly attributed to its adverse effects encompassing immunosuppression, hyperlipidemia, and hyperglycemia [41].”
Aging in the Single-Celled Eukaryote, S. cerevisiae
He, C. Z., & Kennedy, B. K. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1232-8_2 · Cited by 1
Resveratrol Inhibitory Effects Against a Malignant Tumor: A Molecular Insight
Wcisło, G. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813008-7.00018-7 · Cited by 1
Hemin decreases cellular aging and enhances healthspan and lifespan through the AMPK pathwayPreprint
Zhang, Y., Naaz, A., Faidzinn, N. A., Yogasundaram, S., Cheng, T. Y. N., Jing, J. L., Gan, I. W.-H. J. M., Chen, J., & Alfatah, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.15.553367 · Cited by 1
Sobczyk, M. K., & Gaunt, T. R. (2023) · medRxiv · doi:10.1101/2023.10.02.23296427 · Cited by 1
Direct modulation of TRPM8 ion channels by rapamycin and analog macrolide immunosuppressantsPreprint
Tóth, B. I., Bazeli, B., Janssens, A., Lisztes, E., Racskó, M., Kelemen, B., Herczeg, M., Nagy, T. M., Kövér, K. E., Mitra, A., et al. (2024) · eLife · doi:10.7554/elife.97341.1 · Cited by 1
Thioredoxin-1 (Trx1) : a new target in the treatment of cardiovascular diseases
Mahmood, D. F. D. (2014) · theses.fr (ABES) · doi:10.70675/0bee3aa8z1c3cz4eb0z9d80zb78095b7037e · Cited by 2
Filippone, S. M. (2015) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/5ct0-j752 · Cited by 1
The Biology of Aging: Role in Cancer, Metabolic Dysfunction, and Health Disparities
LeBrasseur, N. K., Huffman, D. M., & Denis, G. V. (2014) · Springer eBooks · doi:10.1007/978-3-319-06103-0_5
Doçi, C. L., & Gutkind, J. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-21100-8_7
Stratmann, H. G. (2015) · Science and fiction · doi:10.1007/978-3-319-16015-3_9
Kirkland, J. L., & Tchkonia, T. (2015) · Springer eBooks · doi:10.1007/978-3-319-23246-1_19
Investigating the function of CLU in Alzheimer's Disease in in vitro and in vivo models
Vithal, T. (2016) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17014223.v1
Targeting mTOR: A Little Bit of History and a Large Future
Rowinsky, E. K. (2015) · Springer eBooks · doi:10.1007/978-2-8178-0492-7_1
Closing the Circle: Stem Cell Rejuvenation and Longevity
Florian, M. C., & Geiger, H. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1232-8_16
Ageing of the Stem Cells: The Conjoined Twosome Growing Old: Stem Cell and Its Niche
Lepperdinger, G. (2016) · Healthy ageing and longevity · doi:10.1007/978-3-319-26239-0_5 · Cited by 1
Interaction of type I interferons and mTOR signaling underlying PRRSV infection
Liu, Q. (2016) · K-State Research Exchange (Kansas State University)
Research in Special Populations
Studenski, S. A., & Ferrucci, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802101-9.00029-6 · Cited by 1
Type II Diabetes and Metabolic Syndrome as Risk Factors for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00005-7
Targeting Unselective Autophagy of Cellular Aggregates
Seneci, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801944-3.00004-7
“Anti-aging/neuroprotectant, autophagy inductiondependent effects of rapamycin and rapalogs are observed in vivo [40].”
BackgroundUnselective Disposal of Cellular Aggregates
Seneci, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800186-8.00004-3
Pai, M. (2016) · Common Library Network (Der Gemeinsame Bibliotheksverbund)
Experimental Models and Measurement of Autophagy
Zhu, W., Sun, Y., Tang, Y., Wang, C., Xiao, C.-C., Chen, J.-H., Yu, H., Hu, X.-Y., & Wang, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-805253-2.00005-5
Girard, M.-J. (2013) · Corpus Université Laval (Université Laval)
Kulkarni, R. S., Bajaj, M. S., & Kale, V. P. (2018) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-98146-8_3
A NOVEL APPROACH IN COLORECTAL CANCER AND DIABETES MANAGEMENT: ROLE OF METFORMIN AND RAPAMYCIN
Gerges, A. (2019) · Nova Science Publishers (Nova Science Publishers, Inc.)
The Roles of Primary Cilia in Cardiovascular Diseases and Cancer
Jamal, M. (2020) · Chapman University Digital Commons (Chapman University) · doi:10.36837/chapman.000172
Is Rapamycin an Effective Anti-aging Drug?
Aboud, B. (2020) · The Science Journal of the Lander College of Arts and Sciences
Control Of Systemic Lipid Metabolism By Adipocyte Mtor Signaling
Paolella, L. M. (2020) · Scholarly Commons (University of Pennsylvania)
Postnikoff, S. D. L., Malo, M. E., & Harkness, T. A. A. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3288531
A window for reversibility in pulmonary arterial hypertension
van der Feen, D. E. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.193699260
Vita, D. D. (2021) · Premio Tesi dottorato/Premio Tesi di dottorato · doi:10.36253/978-88-5518-344-4
Longevity as a complex genetic trait
Sutphin, G. L., & Korstanje, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-815962-0.00001-9
Accelerated Lung Aging and Cellular Senescence in COPD
Barnes, P. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00058-5
Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging or Vice Versa?
Hambright, H. G., Hurez, V. J., & Curiel, T. J. (2020) · Springer eBooks · doi:10.1007/978-3-319-57415-8_81
Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging or Vice Versa?
Hambright, H. G., Hurez, V. J., & Curiel, T. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-44870-1_81-1
The articular cartilage: biomechanics and damage in diabetes-induced Charcot neuroarthropathy
Pierre-Jerome, C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99352-4.00025-5
Aging in Stem Cells: Traditional Review
DURMAZ, C., & ŞEN, E. (2022) · Turkiye Klinikleri Journal of Health Sciences · doi:10.5336/healthsci.2021-84348
Disrupted cellular quality control mechanisms in aging
Carvalho, C., Pires, J. F., Moreira, P. I., & Raimundo, N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823761-8.00016-1
Metadata
- Authors
- Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Pennsylvania (US)
- Broad Institute (US)
- Corresponding author
- Baur, Joseph A.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-03-01
- Volume
- 123
- Issue
- 3
- Pages
- 980-989
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3582126
- OpenAlex
- W2129902630
- Cited by
- 531
- References
- 133
- Citations by year
- 2026: 18 · 2025: 32 · 2024: 42 · 2023: 37 · 2022: 41 · 2021: 25 · 2020: 28 · 2019: 44 · 2018: 46 · 2017: 38 · 2016: 57 · 2015: 61 · 2014: 46 · 2013: 16
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Ellison Medical Foundation
- American Federation for Aging Research
- American Heart Association
- Charles A. King Trust
- Starr Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health
- National Institute on Aging (K99AG041765)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- rapamycin, rapalogs, mTOR inhibitors, anti-aging therapeutics, longevity, lifespan extension, mTOR signaling, genetically heterogeneous mice, adverse drug reactions
- MeSH terms
- Aging, Animals, Anti-Inflammatory Agents, Antineoplastic Agents, Autophagy, Humans, Metformin, Neoplasms, Stem Cells, Sirolimus, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.